Ocular Therapeutix, Inc. (OCUL) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Ocular Therapeutix (OCUL) Q1 2026: SOL1 Superiority Data Drives NDA Momentum and 12-Month Disease Control Narrative
  May 05, 2026
• Ocular Therapeutix (OCUL) Q3 2025: $445M Financing Extends Cash Runway, Accelerates Expaxly Phase 3 Ambitions
  November 04, 2025
• Ocular Therapeutix (OCUL) Q2 2025: $97M ATM Raise Extends Runway as Sol Trials De-Risk Superiority Label
  August 05, 2025

Browse all companies